

## 2 Months

Study	Country	Design		VE (95% CI)
Patalon et al., 2021	Israel	TN	H	0.97 (0.95, 0.98)
Lin et al., 2022 (Sep-Nov '21)	USA	С	<del>  ■  </del>	0.81 (0.78, 0.83)
Hulme et al., 2022	UK	MC	<del>  ■  </del>	0.85 (0.82, 0.87)
Florea et al., 2022	USA	MC	<b>⊢</b> ■ <b>⊢</b>	0.89 (0.85, 0.92)
Ranzani et al., 2022	Brazil	MTN	<del>  ■  </del>	0.72 (0.70, 0.74)
Stirrup et al., 2022	UK	С	<del>-</del>	0.81 (0.48, 0.93)
Ng et al., 2022	Singapore	С	<b>├─</b>	0.85 (0.80, 0.89)
Gonzalez et al., 2022	Argentina	MTN	<del>  ■  </del>	0.72 (0.68, 0.75)
Lin et al., 2022 (Dec '21-Jun '22)	USA	С	<b>├──</b> ┤	0.73 (0.69, 0.77)
Ridgway et al., 2022	USA	MCC	<b>├-■</b>	0.76 (0.70, 0.82)
			0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	

## 3 Months

Study	Country	Design		VE (95% CI)
Lin et al., 2022 (Sep-Nov '21)	USA	С	<b>├-■-</b>	0.74 (0.70, 0.78)
Florea et al., 2022	USA	MC		0.79 (0.54, 0.90)
Ranzani et al., 2022	Brazil	MTN	<del>I=I</del>	0.67 (0.65, 0.69)
Stirrup et al., 2022	UK	С		0.85 (0.68, 0.93)
Gonzalez et al., 2022	Argentina	MTN	<del></del>	0.48 (0.39, 0.56)
Lin et al., 2022 (Dec '21-Jun '22)	USA	С	<del>  ■  </del>	0.63 (0.57, 0.68)
Ridgway et al., 2022	USA	MCC	0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	0.76 (0.71, 0.80)